RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 Q2 P&L / Income Statement
2026-04-01 to 2026-06-30
Revenue by Product and Service by Geography
2026-04-01 to 2026-06-30
Swipe to see the full flow
Chart details
RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 Q2 P&L / Income Statement
Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 71,255,000 US dollars
- Cost of sales
- 8,931,000 US dollars
- Gross profit (calculated)
- 62,324,000 US dollars
- Operating expenses (calculated)
- 110,876,000 US dollars
- Loss from operations
- negative 48,552,000 US dollars
- Total other expense, net
- negative 302,000 US dollars
- Loss before income taxes
- negative 48,854,000 US dollars
- Provision for income taxes
- 444,000 US dollars
- Net loss
- negative 49,298,000 US dollars
- License revenue
- 0 US dollars
- Product revenue, net - UNITED STATES
- 50,987,000 US dollars
- Product revenue, net - International
- 20,268,000 US dollars
- Research and development
- 43,428,000 US dollars
- Selling, general, and administrative
- 67,448,000 US dollars
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
87.5%
Gross profit / revenue
Operating margin
−68.1%
Operating profit / revenue
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!